MedTrace Logo

Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

NCT05268718 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-07

No results posted yet for this study

Summary

This clinical study was conducted to evaluate the efficacy and safety of gold-silver cuprous oxide composite nanogels combined with photothermal therapy system in the treatment of severe drug-resistant bacterial keratitis ineffective by traditional antibiotic treatment in human eyes, and to provide translational applications. Based on the clinical evidence, a more effective and safe innovative treatment plan for corneal diseases has been developed.

Conditions

  • Keratitis, Ulcerative
  • Antibiotic Resistance, Microbial
  • Photothermal Therapy

Interventions

DRUG

Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel

Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.

DRUG

Voriconazole eye drops

Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)

OTHER

Normal saline

To be placebo, normal saline were administrated to infectious eye

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Ke Yao, MD · Second Affiliated Hospital of Zhejiang University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-12-31
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268718 on ClinicalTrials.gov